A detailed history of Fjarde Ap Fonden transactions in United Therapeutics Corp stock. As of the latest transaction made, Fjarde Ap Fonden holds 10,800 shares of UTHR stock, worth $3.44 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
10,800
Previous 10,600 1.89%
Holding current value
$3.44 Million
Previous $2.33 Million 6.44%
% of portfolio
0.03%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

BUY
$210.76 - $249.51 $42,152 - $49,902
200 Added 1.89%
10,800 $2.48 Million
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $408,272 - $488,186
1,900 Added 21.84%
10,600 $2.33 Million
Q3 2023

Oct 23, 2023

SELL
$211.82 - $248.24 $21,182 - $24,824
-100 Reduced 1.14%
8,700 $1.97 Million
Q2 2023

Aug 02, 2023

BUY
$205.19 - $232.99 $205,190 - $232,990
1,000 Added 12.82%
8,800 $1.94 Million
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $1.66 Million - $2.15 Million
7,800 New
7,800 $1.75 Million
Q2 2019

Jul 17, 2019

SELL
$76.06 - $120.81 $991,518 - $1.57 Million
-13,036 Closed
0 $0
Q1 2019

Apr 29, 2019

BUY
$107.15 - $126.84 $138,759 - $164,257
1,295 Added 11.03%
13,036 $1.53 Million
Q4 2018

Jan 31, 2019

SELL
$101.4 - $128.73 $324,480 - $411,935
-3,200 Reduced 21.42%
11,741 $1.28 Million
Q2 2018

Jul 12, 2018

BUY
$101.14 - $118.31 $145,338 - $170,011
1,437 Added 10.64%
14,941 $1.69 Million
Q1 2018

May 07, 2018

SELL
$107.21 - $151.94 $42,884 - $60,776
-400 Reduced 2.88%
13,504 $1.52 Million
Q4 2017

Feb 12, 2018

BUY
$118.58 - $151.28 $123,323 - $157,331
1,040 Added 8.08%
13,904 $2.06 Million
Q3 2017

Nov 07, 2017

BUY
$114.6 - $136.81 $11,460 - $13,681
100 Added 0.78%
12,864 $1.51 Million
Q2 2017

Aug 08, 2017

BUY
N/A
12,764
12,764 $1.66 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $14.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Fjarde Ap Fonden Portfolio

Follow Fjarde Ap Fonden and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.